Catalyst

Slingshot members are tracking this event:

FDA Decision Regarding Rigel's (RIGL) New Drug Application for Fostamatinib in Chronic Immune Thrombocytopenia (ITP) Expected in Q1 2018

Source Link:
http://seekingalpha.com/article/4017919-rigel-pharmaceuticals-rigl-ceo-raul-rodriguez-q3-2016-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RIGL
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Apr 17, 2018
Occurred Source:
http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=2343080
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Fostamatinib, Nda, Fda, Chronic Immune Thrombocytopenia, Itp
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.